CAS Medical Systems Inc. named veteran Connecticut biotech executive Thomas M. Patton as president and chief executive of the Branford medical devices maker.
Both Patton’s appointment and former CEO Andrew Kersey’s resignation were effective last Friday, the company said.
Patton, 46, also takes a seat on CAS’ board.
CAS’ main product is its Fore-Sight line of noninvasive bedside devices used to monitor blood pressure in newborns and for detecting oxygen levels in adult surgery patients.
In the second quarter, CAS earned $8,000, or zero cents a share, compared to a loss of $800,000, or 7 cents a share, the same period last year. Revenues were $8.2 million, 4 percent less than the $7.8 million in revenues in the second quarter of 2009.
“We are thrilled to have someone of Tom’s caliber manage our company,” said CAS Chairman Louis P. Scheps.
Scheps praised Patton “as a seasoned executive in the medical products field with a broad range of operational and strategic experience from start-ups to growth companies, both public and private. He has a record of creating shareholder value through the creation of sound strategies and thoughtful execution.
Scheps also thanked Kersey for his service to the company in recent years.
Patton was previously CEO of Wright Medical Group, an orthopedic device company in Memphis, Tenn. He also is a former president of Novametrix Medical Systems, a patient monitoring company in Wallingford.
Most recently, Patton was an advisor to the healthcare-focused private equity group of Ferrer Freeman & Co., LLC, and as CEO of QDx, Inc., a successful start-up that developed a revolutionary platform for hematology diagnostics.
Patton attended The College of the Holy Cross, majoring in economics and accounting. After graduating magna cum laude from Georgetown University Law Center, he worked at the law firm of Williams & Connolly LLP in Washington, DC. Later, he joined Wright Medical as its general counsel, and served that company in various roles until his appointment as CEO.
